AstraZeneca has reported positive outcomes from a planned interim analysis of the double-blind Phase III SERENA-6 trial of camizestrant plus a cyclin-dependent kinase (CDK) 4/6 inhibitor as first-line treatment of individuals with hormone receptor (HR)-positive,

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with the standard-of-care treatment, the company said.

The British drugmaker claimed study success in a first-line setting in breast cancer. Elsewhere, Rezdiffra sales continued to grow and a cancer biotech cut staff.

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the disease getting worse in a study, a positive outcome in the development of the therapy key to the company's pipeline.

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an emergent ESR1 mutation to receive either AZ’s candidate or an aromatase inhibitor (anastrozole or letrozole), both taken alongside a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib).

Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage clinical trial.

AstraZeneca Plc’s experimental breast cancer pill helped patients live for longer without their disease worsening, the UK drugmaker said.